Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics\u2019 innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.
Infinitopes has been featured in a recent blog post by VC Amplify Partners, highlighting its work to prevent cancer recurrence and its approach to advancing precision cancer vaccines.
U-Ploid Biotechnologies has initiated a new collaborative research study with San Diego Fertility Center (SDFC) and Nova Genomics, marking an important translational step in the company\u2019s programme to address the biological causes of age-related infertility.
On its recent visit to Oxford, leading biotech sector commentator Biotech TV had a fascinating and wide-ranging conversation with Dr Jonathan Kwok, the CEO of BioEscalator tenant Infinitopes.
Dr Morrow brings deep expertise in immunology, oncology, and pharmacology, with a strong track record of advancing innovative pipelines from discovery to the clinic. The appointment\r\nreflects growing momentum at Nucleome following the nomination of the first preclinical development candidate, lead candidate NTP464, which is progressing towards IND-enabling studies.
U-Ploid Biotechnologies (U-Ploid), an Oxford-based biotechnology company pioneering first-in-class therapeutics for reproductive health, today announced the appointment of Tim Stonehouse as the company\u2019s first in-house Head of Regulatory Affairs.
What started out as an initiative to embed AstraZeneca into Cambridge's ecosystem has turned into a Science and Business Mentoring programme, AstraZeneca Exchange, which has now been launched at the University of Oxford. So far four BioEscalator tenants who will benefit from this valuable scheme have been named - Infinitopes, Spectre Bio, Granza Bio and ISOgenix Limited.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announced updates to its Board of Directors, including the appointment of Jonathan Montagu, Chief Executive Officer and co-founder of HotSpot Therapeutics, as Board Chair.
The positive feedback from investors and presenting companies at our recent first Cambridge \u2013 Oxford BioVenture Showcase with the Milner Therapeutics Institute shows what a success it was. We will certainly be doing it again!
Financing co-led by Octopus Ventures and new investor Amplify Bio. Company readies its first-in-human clinical trial of ITOP1, a precision cancer vaccine designed to prevent recurrence in oesophageal cancer.
Boehringer Ingelheim has licensed additional Dark Antigens from various tumour types, enhancing Enara\u2019s eligibility for milestone payments under their collaboration. Scott Drutman, M.D., Ph.D. has been appointed as Chief Medical Officer, bringing valuable expertise in translational medicine and immuno-oncology. Enara\u2019s ENA101, a bispecific T-cell engager targeting the DARKFOX antigen, is planned to enter First-in-Human studies in 2026, while the company continues expanding its EDAPT discovery platform to include cell-surface Dark Antigens.
U-Ploid Biotechnologies, a biotechnology company developing next-generation reproductive therapeutics to address age-related fertility decline, today announced that five scientific abstracts have been accepted for presentation at Fertility 2026 in Edinburgh. The presentations take place today, 8 January 2026.
First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases. Evolution of Nucleome\u2019s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need.
In 2022, Oxford Cancer Analytics was voted the company Most Likely to be a Unicorn at that year\u2019s BioEscalator Pitch Battle. Fast forward three years, and the company is well along its growth trajectory. OXcan has graduated from our facility as a fast-scaling diagnostics company, leveraging advanced proteomics and machine learning to develop innovative tests for earlier and more accurate assessment of lung diseases.
In 2024/25, the BioEscalator community achieved remarkable milestones through collaboration with individuals and organisations across the innovation ecosystem. Our annual review, titled \"People and partnerships driving better patient health,\" highlights significant accomplishments and companies such as Oxford Cancer Analytics, with its global perspective. Working with the University of Oxford, alongside tenants and alumni, has been significant in advancing the bioscience industry. This year emphasises our commitment to embracing new ideas while making a meaningful impact.
The BioEscalator is pleased to welcome Akimbo Bio to its community of innovative bioscience start-ups. Co-founded by two Oxford researchers, the company is developing a next-generation immunotherapy platform that leverages intelligent receptor crosstalk to enhance both the efficacy and safety of cancer treatments.
![\"Blue](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-awarded-20ac8-million-in-horizon-europe-2025-grant-funding-to-advance-phase-2-study-of-theo-260-in-ovarian-cancer/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n